Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 5, 1998, Pages 1098-1104

  Preston, Sandra L ^a,b   Drusano, George L ^a   Berman, Adam L ^a   Fowler, Cynthia L ^c   Chow, Andrew T ^c   Dornseif, Bruce ^c   Reichl, Veronica ^c   Natarajan, Jaya ^c   Wong, Frankie A ^c   Corrado, Michael ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c Robert Wood Johnson P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISPOSITION; DRUG DISTRIBUTION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PHARMACOLOGICAL PARAMETERS; PLASMA CLEARANCE; POPULATION MODEL; PRIORITY JOURNAL; PROBABILITY; TREATMENT OUTCOME;

EID: 0031959626     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.5.1098     Document Type: Article

References (12)

1. Anonymous. HPLC assays for the stereospecific determination of levofloxacin in human plasma and urine. Data on file. The R. W. Johnson Pharmaceutical Research Institute, Raritan, N.J.
2. Cockcroft, D. W., and M. H. Gault. 1476. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
3. D'Argenio, O. Z., and A. Schumitzky. 1992. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles.
4. Drusano, G. L. 1991. Optimal sampling theory and population modeling: application to determination of the influence of the microgravity environment on drug distribution and elimination. J. Clin. Pharmacol. 31:962-967.
5. Forrest, A., C. H. Ballow, D. E. Nix, M. C. Birmingham, and J. J. Schentag. 1993. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob. Agents Chemother. 37:1065-1072.
6. Goodwin, A. D., H. A. Gallis, A. T. Chow, F. A. Wong, A. C. Flor, and J. A. Bartlett. 1994. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 38:799-804.
7. Mallet, A. 1986. A maximum likelihood estimation method for random coefficient regression models. Biometrika 73:645-656.
8. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowle, A. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Prospective development of pharmacodynamic relationships between measures of levofloxacin exposure and measures of patient outcome: a new paradigm for early clinical trials. JAMA 279:125-129.
9. Schumitzky, A. 1991. Nonparametric EM algorithms for estimating prior distributions. Appl. Math Comput. 45:143-157.
10. 9a. Schumitzky, A., and R. Jelliffe. Personal communication.
11. Sheiner, L. B., B. Rosenberg, and V. V. Marathe. 1977. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm. 5:445-479.
12. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.